uploads///Pulmicort revenues

AstraZeneca’s Respiratory Drugs: Pulmicort, Daliresp, and Tudorza

By

Dec. 25 2017, Updated 7:30 a.m. ET

Pulmicort’s revenue trends

In 3Q17, AstraZeneca’s (AZN) Pulmicort generated revenues of $242.0 million, which reflected ~8.0% growth on a YoY basis and 7.0% growth quarter-over-quarter. Pulmicort generated 9M17 revenues of $805.0 million, which reflected ~4.0% growth on a YoY basis.

Pulmicort is used for the treatment of asthma attacks in patients aged above six years. In emerging markets, Pulmicort reported 9M17 revenues of $571.0 million, which reflected ~14.0% growth YoY.

The volume growth in China, the Middle East, and North Africa was primarily attributed to the revenue growth of Pulmicort. The revenues from emerging markets contributed to ~71% of Pulmicort’s net revenues.

Article continues below advertisement

Daliresp/Daxas: Revenue trends

Daliresp is used for the treatment of adults with COPD (chronic obstructive pulmonary disease). In 3Q17, Daliresp/Daxas generated revenues of $53.0 million, which represents ~26.0% growth on a YoY basis and 10.0% growth on a quarter-over-quarter basis.

Daliresp/Daxas reported 9M17 revenues of $145.0 million, which reflects ~28.0% growth on a YoY basis.

In 9M17 in the US market, Daliresp generated revenues of $124.0 million, which reflected ~86.0% growth on a YoY basis. Favorable pricing and increasing use of Daliresp primary affected the drug’s revenue growth. In 9M17 outside the US market, Daliresp reported revenues of $21.0 million, reflecting 75.0% growth YoY.

Tudorza’s revenue trends

In 3Q17, Tudorza generated revenues of $37.0 million, which reflected an ~21.0% decline on a YoY basis and 9.0% growth on a quarter-over-quarter basis.

Tudorza reported 9M17 revenues of $108.0 million, which is an ~19.0% decline on a YoY basis. In 9M17 in the US market, Tudorza reported revenues of $47.0 million, which reflected ~23.0% growth YoY.

Tudorza (aclidinium bromide) is used for the long-term maintenance treatment of individuals with COPD. In the marketplace, Tudorza competes with Boehringer Ingelheim’s Atrovent and Novartis’s (NVS) Ultibro Breezhaler.

In September 2017, the FDA approved GlaxoSmithKline’s (GSK) and Innoviva’s (INVA) Trelegy Ellipta for maintenance treatment of individuals with COPD.

AstraZeneca comprises ~0.30% of the Vanguard FTSE Europe ETF (VGK) total portfolio holdings.

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.